Summary
Background
Dyspnea is a common, very distressing symptom in advanced cancer patients that challenges them, their relatives, and healthcare professionals. This narrative review summarizes important literature dealing with the evidence for opioids, benzodiazepines, oxygen, and steroids for treating dyspnea in advanced cancer patients.
Methods
A selective literature search was undertaken in PubMed, Embase, and the Cochrane Library and extended with literature from the reference lists of included studies up to April 2016. Inclusion criteria were that patients were suffering from advanced cancer and were receiving either opioids, benzodiazepines, corticosteroids, or oxygen. The outcome of interest was the reduction of dyspnea measured via a visual analogue scale (VAS), a numerical rating scale (NRS), or a Borg scale. This narrative review describes in detail the findings of 13 studies.
Results
Nine studies deal with the effectiveness of opioids for reducing dyspnea in advanced cancer patients. Five of these found a significant benefit to the use of opioids compared to a placebo. Three found no significant improvements, and two favored combinations of opioids and benzodiazepines. Few high-quality studies were available that used benzodiazepines (n = 3, no difference, significant improvement with midazolam + morphine, significant difference for midazolam) or oxygen (n = 2, both without significant difference). Only one study examined treating dyspnea with steroids in patients with advanced cancer, and that study indicated a benefit of steroids compared to a placebo.
Conclusions
Opioids are the drug of choice for treating refractory dyspnea in advanced cancer patients. Neither benzodiazepines nor oxygen showed significant benefit. In addition, there is insufficient literature available to draw a conclusion about the effectiveness of steroids for treating persistent dyspnea in advanced cancer patients.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10354-017-0600-4/MediaObjects/10354_2017_600_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10354-017-0600-4/MediaObjects/10354_2017_600_Fig2_HTML.gif)
Similar content being viewed by others
Abbreviations
- COPD:
-
Chronic obstructive pulmonary disease
- CRF:
-
Cancer-related fatigue
- ESAS:
-
Edmonton Symptom Assessment Scale
- ESMO:
-
European Society for Medical Oncology
- NH:
-
Nebulized hydromorphone
- NRS:
-
Numeric rating scale
- NS:
-
Nebulized saline
- RCT:
-
Randomized controlled trials
- VAS:
-
Visual analog scale
References
Dyspnea ATSCo. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med. 1999;159(1):321–40.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung L‑, version 1.0, AWMF-Registernummer: 128/001OL.
Pohl G, Gaertner J. Pathophysiology and diagnosis of dyspnea in patients with advanced cancer. Wien Med Wochenschr. 2009;159(23–24):571–6.
Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–52.
Bausewein C, Simon ST. Shortness of breath and cough in patients in palliative care. Dtsch Arztebl Int. 2013;110(33–34):563–71. quiz 72.
Guirimand F, Sahut d’izarn M, Laporte L, Francillard M, Richard JF, Aegerter P. Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancer. Cancer Med. 2015;4(4):532–9.
Weingartner V, Bausewein C, Higginson IJ, Scheve C, Murtagh FE, Voltz R, et al. Characterizing episodic breathlessness in patients with advanced disease. J Palliat Med. 2013;16(10):1275–9.
Bulbul Y, Ozlu T, Arinc S, Ozyurek BA, Gunbatar H, Senturk A, et al. Assesment of palliative care in lung cancer in Turkey (ASPECT study). Eur Respir J. 2015; https://doi.org/10.1183/13993003.congress-2015.PA4843.
Currow DC, Smith J, Davidson PM, Newton PJ, Agar MR, Abernethy AP. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage. 2010;39(4):680–90.
Mercadante S, Aielli F, Adile C, Valle A, Fusco F, Ferrera P, et al. Epidemiology and characteristics of episodic breathlessness in advanced cancer patients: an observational study. J Pain Symptom Manage. 2015;51:17–24.
Kloke M, Cherny N, Committee EG. Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelinesdagger. Ann Oncol. 2015;26(Suppl 5):v169–v73.
Ost DE, Ernst A, Grosu HB, Lei X, Diaz-Mendoza J, Slade M, et al. Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. Chest. 2015;147(5):1282–98.
Steffen ST, Higginson IJ, Booth S, Harding R, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2010; 1. https://doi.org/10.1002/14651858.CD007354.pub2.
Simon ST, Higginson IJ, Booth S, Harding R, Weingartner V, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016; https://doi.org/10.1002/14651858.CD007354.pub3.
Simon ST, Koskeroglu P, Bausewein C. Pharmacological therapy of refractory dyspnoea : a systematic literature review. Schmerz. 2012;26(5):515–22.
Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, et al. Dexamethasone for dyspnea in cancer patients: a pilot double-blind, randomized, controlled trial. J Pain Symptom Manage. 2016;52(1):8–16.e1.
Allard P, Lamontagne C, Bernard P, Tremblay C. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage. 1999;17(4):256–65.
Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2001;57(11):939–44.
Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med. 1993;119(9):906–7.
Davis CPK, A’Hern R, et al. Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliat Med. 1996;10:64–5.
Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523–8.
Bruera E, Sala R, Spruyt O, Palmer JL, Zhang T, Willey J. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005;29(6):613–8.
Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage. 2008;36(1):29–38.
Hui D, Xu A, Frisbee-Hume S, Chisholm G, Morgado M, Reddy S, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. J Pain Symptom Manage. 2014;47(2):209–17.
Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016; https://doi.org/10.1002/14651858.cd011008.pub2.
Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939–44.
Harrison, TJR. A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer [dissertation]. Bristol: Bristol University, 2004.
Navigante AH, Cerchietti LC, Castro MA, Lutteral MA, Cabalar ME. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage. 2006;31(1):38–47.
Navigante. Morphine versus midazolam as upfront therapy to relief dyspnea in ambulatory cancer patients while its underlying cause is sought or treated. (unpublished).
Navigante AH, Castro MA, Cerchietti LC. Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage. 2010;39(5):820–30.
Uronis HE, Currow DC, McCrory DC, Samsa GP, Abernethy AP. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. Br J Cancer. 2008;98(2):294–9.
Ahmedzai SH, Laude E, Robertson A, Troy G, Vora V. A double-blind, randomised, controlled phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion. Br J Cancer. 2004;90(2):366–71.
Booth S, Kelly MJ, Cox NP, Adams L, Guz A. Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med. 1996;153(5):1515–8.
Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet. 1993;342(8862):13–4.
Bruera E, Sweeney C, Willey J, Palmer JL, Strasser F, Morice RC, et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med. 2003;17(8):659–63.
Philip J, Gold M, Milner A, Di Iulio J, Miller B, Spruyt O. A randomized, double-blind, crossover trial of the effect of oxygen on dyspnea in patients with advanced cancer. J Pain Symptom Manage. 2006;32(6):541–50.
Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE 2nd, Marcello J, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet. 2010;376(9743):784–93.
Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076–82.
Blinderman CDB, Billings JA. Comfort care for patients dying in the hospital. N Engl J Med. 2016;374(17):1692–3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
M. Strieder, M. Pecherstorfer, and G. Kreye declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Strieder, M., Pecherstorfer, M. & Kreye, G. Symptomatic treatment of dyspnea in advanced cancer patients. Wien Med Wochenschr 168, 333–343 (2018). https://doi.org/10.1007/s10354-017-0600-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10354-017-0600-4